FDA OKs Second Samsung BioLogics’ Biomanufacturing Facility in Korea
By
The US Food and Drug Administration (FDA) has licensed Samsung BioLogics’ biomanufacturing facility in Incheon, South Korea for monoclonal antibody drug substance production. Samsung BioLogics is a contract biologics manufacturer.…
Lupin Completes $150-Million Acquisition of Symbiomix Therapeutics
By
Lupin, a Mumbai, India-headquartered pharmaceutical company, has completed its $150-million acquisition of Symbiomix Therapeutics, a Newark, New Jersey-headquartered biotechnology company. Lupin agreed to acquire the company earlier in 2017. The…
Xellia To Invest $25 Million to Expand Sterile Drug Product Manufacturing
By
Xellia Pharmaceuticals, a Copenhagen, Denmark-headquartered specialty pharmaceutical company focused on anti-infective treatments, has broken ground on a new $25-million facility for sterile manufacturing at its Copenhagen site, which is the…